A 24A 24-month, double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis To compare FTY720 1.25 mg and 0.5 mg with placebo and to demonstrate that at least the 1.25 mg FTY720 dose is superior to placebo as assessed by the annual relapse rate in patients with RRMS treated u...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, double-dummy, active (formoterol 12 µg b.i.d) and placebo controlled, multi-center, 5 period crossover, dose-ranging study to assess the bronchodilatory efficacy and safety of single doses of indacaterol 150 µg, 300 µg and 600 µg delivered via single dose dry powder inhaler (SDDPI) vs. placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD) To assess the bronchodilatory efficacy of single doses of indacaterol 150 µg, 300 µg & 600 µg via SDDPI in patients with moderate to severe COPD as compared to placebo in terms of 24 h post-dose (trou...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration of formoterol Comparison of the responsiveness and variability of Mean Maximal Change in percent predicted FEV1 from baseline with Mean Maximal Change in IC from baseline following single doses of indacaterol and m...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.) in patients with chronic obstructive pulmonary disease, using formoterol (12 µg b.i.d.) as an active control To assess indacaterol (300 & 600 µg o.d. via SDDPI) superiority in patients with COPD as compared to placebo with respect to 24 h post dose (trough) FEV1 after 12 weeks of treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, multi-center, double-blind, placebo-controlled, parallel-group trial to explore the effects of 78 weeks omalizumab treatment as add on therapy on airway inflammation and remodeling in patients with moderate to severe IgE-mediated asthma receiving inhaled corticosteroids and long acting beta-agonists To explore the effect of 78-weeks therapy with omalizumub compared to placebo on the number of sub-epithelial eosinophils, a marker of airway inflammation, in patients with resistent moderate to sever...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune